Skip to content
AnalystLens

IDEXX Laboratories 8-K Report, Financial Results (Feb 2, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 2, 2026
Period End
February 2, 2026
Security
IDXX
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Nov ’20Nov ’20
  2. Material agreement8-K · Oct ’22Oct ’22
  3. Leadership change8-K · Feb ’25Feb ’25

Summary

Summary of the 8-K filed February 2, 2026. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories reported strong fourth quarter 2025 results, with revenue of $1,091 milliona, up 14% as reported and 12% organically, and EPS of $3.08, up 18% as reported and 17% on a comparable basis.

Growth was led by Companion Animal Group (CAG) Diagnostics recurring revenue, which rose 12% as reported and 10% organically, with international regions and U.S. both growing at or above sector levels. Operating margin expanded 150 basis points to 28.9%, and management cited over 1,900 IDEXX inVue Dx placements, a quarterly record for instrument placements. Full-year 2025 revenue reached $4,304 millionb (up 10% as reported and organically), and reported EPS of $13.08 rose 23%, though comparable EPS growth was 14% after adjusting for a prior-year litigation accrual and other items.

For 2026, IDEXX issued initial guidance calling for revenue of $4,632 million to $4,720 millionc (7.6% to 9.6% reported growth, 7.0% to 9.0% organic) and EPS of $14.29 to $14.80 (9% to 13% reported growth, 10% to 14% comparable). Guidance assumes roughly 4% net price benefit in CAG Diagnostics recurring revenue, a targeted 40 to 90 basis points of reported operating margin improvement, and free cash flow conversion of 85% to 95% of net income. Investors will want to weigh strong momentum against the fact that the 2026 revenue outlook implies some deceleration from the 10% organic growth achieved in 2025, and that Q4 benefited from favorable currency and tax items.

The filing is a routine furnishing of an earnings press release under Item 2.02 and is not deemed filed under the Exchange Act. It contains no material new contractual, legal, or governance events beyond the results and outlook themselves.

Key Highlights

  1. Q4 2025 revenue of $1,091 million grew 14% as reported and 12% organically; CAG revenue grew 15% as reported and 13% organically.
  2. CAG Diagnostics recurring revenue grew 12% as reported and 10% organically in Q4, with international growth of 17% reported and 12% organic and U.S. growth of 9%.
  3. Q4 instrument revenue in CAG Diagnostics rose 76% as reported, driven by over 1,900 IDEXX inVue Dx placements and nearly 1,400 new and competitive Catalyst placements.
  4. Q4 operating margin expanded 150 basis points to 28.9% as reported (120 bps comparable), and Q4 diluted EPS of $3.08 rose 18% as reported and 17% comparable, aided by $0.09 of currency benefit and $0.07 of share-based compensation tax benefits.
  5. Full-year 2025 revenue of $4,304 million grew 10%, and free cash flow was $1,057 million, equal to roughly 100% of net income of $1,059 million.
  6. 2026 guidance calls for revenue of $4,632 million to $4,720 million (7.0% to 9.0% organic) and EPS of $14.29 to $14.80, with a targeted 40 to 90 bps of reported operating margin expansion.
  7. The company repurchased $1.22 billion of stock in 2025 and expects a 1% to 2% reduction in average shares outstanding in 2026, while projecting roughly $180 million in capital expenditures.

Frequently Asked Questions

  1. What drove IDEXX's strong fourth quarter 2025 performance?

    Growth was led by CAG Diagnostics recurring revenue, which rose 12% as reported and 10% organically. Drivers included net customer gains, benefits from IDEXX innovation such as IDEXX inVue Dx and Cancer Dx, and expansion of the premium instrument installed base, which grew 12% year over year. VetLab consumables grew 17% as reported, while rapid assay products declined 2% as volumes shifted to the Catalyst Pancreatic Lipase Test.

  2. How does 2026 guidance compare with 2025 results?

    The company guided to 2026 revenue of $4,632 million to $4,720 million, or 7.6% to 9.6% reported growth, compared with 10% growth in 2025. Organic growth guidance of 7.0% to 9.0% is below the 10% organic growth achieved in 2025. EPS guidance of $14.29 to $14.80 implies 9% to 13% reported growth, or 10% to 14% on a comparable basis, against 2025 reported EPS of $13.08. Guidance includes an estimated 4% net price benefit in CAG Diagnostics recurring revenue and about a 0.6% currency benefit to revenue.

  3. Were there one-time items that affected the reported 2025 earnings growth?

    Yes. Full-year 2025 reported EPS growth of 23% was flattered by lapping a $0.56 per share negative impact from a litigation accrual in 2024. The comparable EPS growth of 14% excludes this and other items, including $0.35 of share-based compensation tax benefits and $0.10 of currency benefit. Management also noted that the 2025 Q1 litigation accrual reduction and the now-concluded litigation matter, which was paid in April 2025 at about $80 million, are not expected to recur.

  4. What is the outlook for margins and cash generation in 2026?

    Management targets 40 to 90 basis points of reported operating margin expansion in 2026, bringing operating margin to 32.0% to 32.5%. Operating cash flow is expected to be 105% to 115% of net income, and free cash flow 85% to 95% of net income. Capital expenditures are projected at about $180 million, up from roughly $125 million in 2025, reflecting higher investment in the business. Interest expense is estimated at about $34 million, and the effective tax rate at about 21.3%.